# An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers

> **NCT01466335** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 39 (actual)

## Conditions studied

- Bone Marrow Transplantation

## Interventions

- **DRUG:** Ronacaleret (100mg tablet)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01466335
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-27
- **Primary completion:** 2012-03-05
- **Final completion:** 2012-03-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466335, "An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01466335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*